Fate Therapeutics Company
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
Investors
Connections from
Headquarters:
United States
Number Of Exists:
N/A
Total Funding:
$360.2M
Founded Date:
2007
Employee Number:
11-50
Investment Stage:
N/A
Last Funding Type:
Post-IPO Equity
Investor Type:
N/A
Investors Number:
7
Technology:
mHealth
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Industry:
Genomic and Epigenominc Instabillity